NZ599791A - Therapeutic peptides - Google Patents

Therapeutic peptides

Info

Publication number
NZ599791A
NZ599791A NZ599791A NZ59979110A NZ599791A NZ 599791 A NZ599791 A NZ 599791A NZ 599791 A NZ599791 A NZ 599791A NZ 59979110 A NZ59979110 A NZ 59979110A NZ 599791 A NZ599791 A NZ 599791A
Authority
NZ
New Zealand
Prior art keywords
amino acid
group
groups
cyclic
hydrogen atoms
Prior art date
Application number
NZ599791A
Other languages
English (en)
Inventor
Martina Havelkova
Morten Strom
Terkel Hansen
Veronika Torfoss
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of NZ599791A publication Critical patent/NZ599791A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ599791A 2009-11-02 2010-11-02 Therapeutic peptides NZ599791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0919194.1A GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds
PCT/GB2010/002024 WO2011051692A1 (en) 2009-11-02 2010-11-02 Therapeutic peptides

Publications (1)

Publication Number Publication Date
NZ599791A true NZ599791A (en) 2014-10-31

Family

ID=41435032

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599791A NZ599791A (en) 2009-11-02 2010-11-02 Therapeutic peptides

Country Status (14)

Country Link
US (1) US8809280B2 (enExample)
EP (1) EP2496596B1 (enExample)
JP (1) JP5810090B2 (enExample)
KR (1) KR101730680B1 (enExample)
CN (1) CN102762586B (enExample)
AU (1) AU2010311186B2 (enExample)
CA (1) CA2777749C (enExample)
DK (1) DK2496596T3 (enExample)
ES (1) ES2621188T3 (enExample)
GB (1) GB0919194D0 (enExample)
NZ (1) NZ599791A (enExample)
PL (1) PL2496596T3 (enExample)
RU (2) RU2548905C2 (enExample)
WO (1) WO2011051692A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI579296B (zh) 2011-12-28 2017-04-21 Chugai Pharmaceutical Co Ltd Cyclization of Peptide Compounds
HUE059925T2 (hu) 2015-03-13 2023-01-28 Chugai Pharmaceutical Co Ltd Módosított aminoacil-tRNS-szintetáz és alkalmazása
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
US20190145962A1 (en) * 2016-04-14 2019-05-16 Tao Health Life Pharma Co., Ltd. Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
JP7187323B2 (ja) 2017-01-31 2022-12-12 中外製薬株式会社 無細胞翻訳系におけるペプチドの合成方法
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds
WO2018188761A1 (en) 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
JP7229158B2 (ja) 2017-06-09 2023-02-27 中外製薬株式会社 N-置換アミノ酸を含むペプチドの合成方法
US11492369B2 (en) 2017-12-15 2022-11-08 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide, and method for processing bases
JP7279073B2 (ja) 2018-11-07 2023-05-22 中外製薬株式会社 O-置換セリン誘導体の製造方法
KR20210098476A (ko) 2018-11-30 2021-08-10 추가이 세이야쿠 가부시키가이샤 펩티드 화합물 또는 아마이드 화합물의 탈보호법 및 고상 반응에 있어서의 탈수지 방법, 및 펩티드 화합물의 제조 방법
CN120518504A (zh) 2019-03-15 2025-08-22 中外制药株式会社 芳香族氨基酸衍生物的制备方法
CN110294793B (zh) * 2019-06-24 2023-10-27 合肥科生景肽生物科技有限公司 Sumo荧光探针及其制备方法
IL292140B1 (en) 2019-11-07 2025-10-01 Chugai Pharmaceutical Co Ltd A cyclic peptide compound with KRAS inhibitory activity
CN114790151B (zh) * 2022-02-14 2023-03-31 湖南省湘中制药有限公司 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法
EP4637800A1 (en) 2022-12-20 2025-10-29 Lytix Biopharma AS Compositions comprising an oncolytic peptide and chitosan

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342705A (en) 1979-11-23 1982-08-03 Monsanto Company Methylene thioethers
GR79206B (enExample) 1982-06-03 1984-10-22 Montedison Spa
IT1161927B (it) 1983-03-31 1987-03-18 Montedison Spa Furano-derivati ad attivita' fungicida
DK523288A (da) 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
US5593967A (en) 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
WO1992004045A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Novel cholecystokinin antagonists, their preparation and therapeutic use
US5387671A (en) 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5885782A (en) 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
CZ297544B6 (cs) 1996-01-02 2007-02-07 Aventis Pharmaceuticals Inc. Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
DE102006018080A1 (de) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide
CN101528248B (zh) * 2006-07-10 2015-11-25 Pba3生物医学有限责任公司 抗微生物肽
GB0724951D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
ATE482186T1 (de) * 2008-03-18 2010-10-15 Univ Dresden Tech Modulares gerüst zur gestaltung von spezifischen molekülen zur verwendung als pepitmimetika und hemmer für die proteininteraktion

Also Published As

Publication number Publication date
RU2015111706A (ru) 2015-11-10
KR20120104986A (ko) 2012-09-24
PL2496596T3 (pl) 2017-08-31
AU2010311186A1 (en) 2012-05-31
US8809280B2 (en) 2014-08-19
JP5810090B2 (ja) 2015-11-11
EP2496596B1 (en) 2017-01-11
JP2013509389A (ja) 2013-03-14
RU2012121264A (ru) 2013-12-10
CN102762586B (zh) 2016-10-05
RU2548905C2 (ru) 2015-04-20
WO2011051692A1 (en) 2011-05-05
AU2010311186B2 (en) 2015-09-24
CA2777749A1 (en) 2011-05-05
KR101730680B1 (ko) 2017-04-26
CN102762586A (zh) 2012-10-31
ES2621188T3 (es) 2017-07-03
RU2015111706A3 (enExample) 2018-10-29
US20130035296A1 (en) 2013-02-07
RU2676713C2 (ru) 2019-01-10
DK2496596T3 (en) 2017-04-03
BR112012010333A2 (pt) 2016-03-29
CA2777749C (en) 2019-08-06
EP2496596A1 (en) 2012-09-12
GB0919194D0 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
NZ599791A (en) Therapeutic peptides
BRPI0909823A2 (pt) conjugados antagonistas de peptídeo análogo de bombesina
UY33605A (es) Profarmacos que comprenden un conjugado de conector de exendina
MX2012001399A (es) Profarmacos que comprenden un conjugado de insulina-conector.
WO2012054500A3 (en) Compositions for drug administration
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
NZ596617A (en) Melanocortin receptor-specific peptides
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
ATE495197T1 (de) Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel
MY153979A (en) Substituted piperidino-dihydrothienopyrimidine
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
JP2013509389A5 (enExample)
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX2009001452A (es) Peptidos que tienen actividad farmacologica para tratar trastornos asociados con migracion celular alterada, tal como cancer.
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
JP2018515614A5 (enExample)
MX2010010177A (es) Fragmentos de beta timosina mejorada.
WO2012031023A3 (en) Treatment of inflammatory bowel diseases using a tripeptide

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 NOV 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20150515

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2018 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20171024

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20181024

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20191024

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20201024

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2022 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20221021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2024 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20231024

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2025 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2026 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20251021